Background and aim: Lipoprotein-apheresis (LA) is a therapeutic approach used against severe forms
INTRODUCTION
Patients with severe forms of dyslipidemia are subject to atherosclerosis and subsequent coronary ischemic events and thus require an intensive, effective, continuous, and personalized form of treatment [1] . Therefore, patients who are poor-or non-responders, or intolerant to pharmacological treatments require alternative therapeutic approach such as LA. In Germany, LA is currently representing the treatment of choice for patients not reaching the target levels of LDL-C under a maximum cholesterol lowering treatment approach such as PCSK9 inhibitors, and patients suffering from elevated lipoprotein(a) (Lp(a)). In other countries, LA is only performed to a very limited extent, mainly in patients with homozygous familial hypercholesterolemia (HoFH).
The extracorporeal treatment is highly effective, but may exert additional effects by triggering an immunologic response via blood-biomaterial interactions. Recent investigations confirmed that LA not only show acute lipid-lowering and cholesterol-lowering effects, but also efficacy in reducing several plasmatic pro-inflammatory cytokines. On the other hand, there is evidence that the complement system, postulated to be of pathogenic importance for development of atherosclerotic lesions [2 [2] [3] [4] [5] [6] [7] [8] [9] [10] ], gets activated by LA treatment due to bio-incompatibility and thus increases the M A N U S C R I P T
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amount of systemic complement activation products [3] . However, there is also data suggesting that surfaces might bind complement components thereby reducing complement activation during the LA process [4] . These non-lipid-lowering effects can be defined as pleiotropic or pleiotropic-equivalent and may be both pro-and anti-inflammatory. The net result of these reactions is important to the patient [5] and measures to attenuate the inflammatory responses elicited by the extracorporeal treatment should be taken to obtain optimal bio-compatibility.
The presence of T cells in human atherosclerotic plaques has been described in 1985 [6] . A few years later, MHC class II and IFN-γ were found in lesions, and antibodies to oxidized low-density lipoprotein (LDL) were described [7] . Today, the concept that atherosclerosis is an inflammatory disease is no longer controversial [8] , and investigations on how this inflammation is regulated have emerged. In this regard, T cells are of particular interest, both because of their secretion of mediators that influence plaque development and because their activity depends on the triggering of specific antigens that are found within the disease site. T cells are regulated by soluble and membrane-bound molecules from many cell types and, in turn, they act on most other cells. This network of cell-to-cell interactions affects the development of many inflammatory and autoimmune diseases.
In this context, we decided to investigate the potential effects of dyslipidemia and LA on the regulation of CD4 + T cells activation and induction in dyslipidemic patients, with a particular regard on the pro-/ anti-inflammatory secreted cytokines balance.
MATERIAL AND METHODS

Patients and ethics
The study was reviewed by the local ethics committee and all subjects gave written informed consent. In a pilot approach, a total number of 5 patients undergoing stable weekly LA treatment at the Extracorporeal Treatment and Apheresis Center of the University Hospital Carl Gustav Carus in Dresden were investigated. To perform the analyses, heparinized blood was collected immediately M A N U S C R I P T
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prior to and following a single LA session. Samples were sent to King's College London for further analysis. All findings were compared to an age-and gender-matched healthy cohort.
Reagents
Cell-stimulating mAbs were purified from a specific hybridoma (anti-CD3; OKT-3) or generated inhouse (anti-CD46; TRA-2-10) [9] .
T cell isolation and activation
PBMCs were separated to CD4 + T cells using the MACS human CD4 + Positive T Cell Isolation Kit (Miltenyi Biotech Ltd, Bisley, UK) according to manufacturer's instructions. Purity of isolated lymphocyte fraction was typically >97 %. CD4 + T cells were activated by 36 h incubation at 37°C in complete RPMI medium in 48-well culture plates (2.5 -3.0 x 10 5 cells/well) coated with mAbs to CD3 or CD3 + CD46 (2.0 μg/ml PBS each) and addition of 25 U/ml rhIL-2.
Cytokine measurements
Cytokine production and secretion by CD4 + T cells was measured using the Th1/Th2/Th17 Cytokine Bead Array kit (560484, BD Biosciences) according to manufacturer's instructions and a LSR Fortessa Cytometer (BD Biosciences).
Statistics
Numerical data are presented with mean and standard error mean (SEM). Levels before LA versus after LA or versus healthy donors were compared by unpaired t tests. All tests were two tailed, and results with p<0.05 were considered statistically significant (*). Analyses were performed using PRISM 6 (Graph Pad Software Inc, La Jolla, CA). Interestingly, after CD3 + CD46 activation, the IL-17A secretion rates doubled compared to CD3 activation alone.
RESULTS
Dyslipidemia
In all the conditions of activation, TNF-α secretion rates were slightly higher in the LA patients compared to healthy donors, but the difference did not reach a statistical significance. Therefore, our results demonstrate that LA does not induce a significant increase in TNF-α secretion by activated 
Dyslipidemia and LA impact the release of anti-inflammatory cytokines IL-10 and IL-4
While not significant in this limited cohort, differences seem to develop in IL-10 secretion between cells from dyslipidemic and healthy donors after CD3 and CD3 + CD46 activation. After CD3 activation, CD4 + T cells from patients before LA secreted 4 times more IL-10 than cells from healthy donors and this increase was amplified to 5 times in the same patients after LA (FIG 3A) . As expected, CD3 + CD46 activation increased IL-10 secretion in healthy donors as well as in dyslipidemic patients but surprisingly, this augmentation was more marked in dyslipidemic patients after LA, with values 6 times higher than in healthy donors (FIG 3A) .
In this setting, IL-4 secretion from activated CD4 + T cells was only slightly increased in LA patients either before or after treatment when compared to healthy donors for which IL-4 secretion was null in all the conditions as expected (FIG 3B) . Nevertheless, regarding the very low amounts of IL-4 secreted in our experimental conditions, we can interrogate about the physiological relevance of this observation.
DISCUSSION
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In this pilot study, we compared the cytokines secretion profiles from CD4 + T cells isolated from 5 healthy donors and from 5 dyslipidemic patients before and after LA. The secretion profiles were analysed after CD3 (TCR alone) and CD3 + CD46 co-activation, with a particular regard on the pro-/ anti-inflammatory cytokines balance and on the NLRP3 inflammasome activation, since a complement-NLRP3 axis in CD4 + T cells has been recently described as a novel potential therapeutic target for the modulation of Th1 activity in autoimmunity and infection in humans [10] .
Dyslipidemia promotes alterations in CD3 + CD46 co-activation mechanisms in CD4 + T cells
In humans, CD46 is a widely distributed transmembrane glycoprotein that inhibits complement activation on host cells and CD46 engagement was shown to induce low IFN-γ, and high IL-10 in naïve CD3-activated CD4 + T cells, a phenotype shared with Tr1 cells. Therefore, CD46 plays an important role in the regulation of adaptive immunity and his deficiency is associated with chronic inflammation and autoimmune diseases [11] . Surprisingly, in LA patients, CD46 co-activation of CD4 + T cells induced an important increase in IFN-γ secretion. This effect could be due to a dysfunction in the CD46-dependant signalling pathways in activated CD4 + T cells and could induce their incapacity to switch from a Th1 to a Tr1 phenotype, thus promoting a deleterious inflammatory state in patients with dyslipidemia. More importantly, this effect tends to be amplified by LA (p=0.0643). In parallel, IL-2 secretion rates were significantly increased after CD46 co-activation in LA patients compared to healthy donors and this effect also tends to be amplified by the treatment. This could be related to deleterious biomaterial interactions which promote activation of signalling pathways inducing proinflammatory cytokines secretion in CD4 + T cells.
Pro-inflammatory cytokines secretion by activated CD4 + T cells is globally increased in dyslipidemic patients and LA tends to amplify this effect
The pro-inflammatory cytokines investigated herein included IFN-γ, IL-2, IL17A, TNF-α and IL-6.
The principal Th1 cytokine, IFN-γ, is produced by most T cells, including CD4 + , in the human atherosclerotic plaque [7] . IFN-γ potentiates most stages that lead to inflammation in atherosclerosis M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT [12] but surprisingly, a study demonstrated that LDLR −/− mice transplanted with bone marrow from IFN-γ −/− mice exhibited larger atherosclerotic lesions than mice that received bone marrow from IFN-γ +/+ mice [13] , implicating a protective role of IFN-γ which also possesses certain potentially antiatherosclerotic properties in vitro [12] . Thus, interpretation on the global in vivo effects of LA on IFN-γ secretion by CD4 + T cells is complex.
IL-2 is produced mainly by activated Th1 cells and is an important regulator of the immune response and homeostasis. It also plays a central role in downregulating immune responses and its absence results in severe autoimmunity [14] . Interestingly, recent studies have indicated that a major function of the IL-2/IL-2 receptor system lies in directing development and function of T regulatory cells (Tregs) [15] . In atherosclerotic diseases, high levels of IL-2 have been detected in atheromatous plaques [16] but despite this evidence, the role of IL-2 in the pathogenesis and/or in the progression of various atherosclerotic diseases has not yet been determined. Our study suggest that the high levels of IL-2 associated with dyslipidemia could be partially explained by an over secretion of this cytokine by CD46 co-activated CD4 + T cells. The fact that LA could trigger this effect might, again, reflect alterations of the CD46-mediated signalling pathways in these cells after LA, resulting in their incapacity to regulate the transition from innate to adaptive immunity (even in the presence of high IL-2 concentrations), therefore promoting pro-atherosclerotic effects and decreasing the efficacy of the treatment.
We also observed a tendency for IL-17A secretion to be increased in LA patients compared to healthy donors, this effect being more marked after CD46 co-activation. This result might reflect the tendency of a CD4 + T cells pool to differentiate into Th17 lymphocytes in dyslipidemic patients. This is in accordance with previous observations by other groups which reported the presence of Th17 cells in human atherosclerotic lesions [17] . The role of IL-17A in atherosclerosis is still under debate, however the overall data indicate that enhanced IL-17A production associated with increased IL-10 (regulatory Th17) and reduced IFN-γ will most probably limit lesion development and promote
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plaque stability. In contrast, dual production of IL-17A and IFN-γ will most likely promote lesion progression and instability [18] . Intriguingly, recent evidences showed that both Th17 cells and immunosuppressive Tregs derived from naïve CD4 + cells and can be reciprocally induced, contingent upon the presence of either IL-6 or IL-2, respectively, in the presence of TGF [19] . Furthermore, it has been shown that Tregs exhibit "plasticity" and can become IL-17-producing cells after treatment with IL-6 both in vitro [20] and in vivo [21] . Therefore, considering our results and the increased secretion of IL-17A, IFN-γ and IL-10 together with the slight decrease in IL-6 secretion in CD46 co-activated CD4 + T cells from dyslipidemic patients, interpretation of the interplay between these cytokines, the resulting net effect on T cells differentiation and impact on atherosclerosis development is highly hazardous. We can however, speculate on the existence of a Th17 pool of T cells resulting from the IL-6 stimulated dedifferentiation of Tregs that would promote inflammation in dyslipidemic patients.
This hypothesis is in range with previous results clearly associating high levels of circulating IL-6 with dyslipidemia and atherosclerosis development [22] .
TNF-α is produced by Th1 cells as well as macrophages and other cell types. TNF-α is a proinflammatory cytokine and promotes several autoimmune diseases. In addition, TNF-α inhibits lipoprotein lipase, leading to hypertriglyceridemia and reduced fatty acid oxidation, and stimulates production of oxygen and nitrogen radicals [23] . Here, we observed a slight increase of TNF-α secretion by activated and co-activated CD4 + T cells in LA patients before treatment which is in line with previous observations. Interestingly, following LA, patients presented a level of secretion comparable to healthy donors, suggesting that LA could be responsible for the removal of TNF-α secretion stimulators, therefore reducing its pro-inflammatory and pro-atherogenic effects in dyslipidemic patients.
We did not observe any significant changes in IL-6 secretion by activated CD4 + T cells in our conditions, but a tendency for a decrease in LA patients before and after treatment compared to controls. It is surprising since elevated circulating IL-6 rates have been clearly associated with M A N U S C R I P T
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dyslipidemia and the progression of atherosclerosis. On the other hand, several types of immune cells secrete IL-6, including Th2 lymphocytes. Moreover, IL-17A acts on a variety of cells to induce the production of cytokines, including IL-6 and TNF-α [24] . Therefore, this result tends to suggest that CD4 + T cells are not involved in the increased circulating IL-6 rates observed in patients with dyslipidemia. However, high levels of IL-6 in dyslipidemic patients could be responsible for the dysregulation of CD4 + T cells activation and induction.
Anti-inflammatory cytokine IL-10 secretion by CD4 + T cells tends to increase after CD46 coactivation and LA amplifies this effect
We also measured IL-10, a cytokine that is mainly produced by Th2 lymphocytes, and to a lesser extent by monocytes, macrophages and activated T lymphocytes. IL-10 inhibits the production of Thus, we postulate that a similar mechanism could occur in dyslipidemic patients and that this particular phenotype is further modulated by intrinsic effects of LA.
Complement-NLRP3 inflammasome axis could be involved in the particular cytokines secretion pattern in CD4 + T cells from LA patients before and after treatment
It has been recently demonstrated that certain LA systems are associated with an elevated circulating rate of alternative complement products C3a and Bb [29] . The complement system has recently begun to attract interest as a therapeutic target since complement components might enhance production of IL-1b [30] which is critically involved in several inflammatory diseases [30] .
However, it is unknown whether, or how, complement and IL-1b are linked. One possibility is that the interaction of complement system with TLRs on phagocytes enhances the activation of the NLRP3 inflammasome and promotes maturation of the pro-inflammatory cytokines IL-1b and IL-18 [31] . This 
Isolated CD4
+ T cells from dyslipidemic and healthy donors were activated with TCR alone (CD3), coactivated with CD3 and CD46 antibodies or maintained non-activated for 36h, then the concentrations of secreted cytokines were measured by cytometry. 
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Isolated CD4
+ T cells from dyslipidemic and healthy donors were activated with TCR alone (CD3), coactivated with CD3 and CD46 antibodies or maintained non-activated for 36h, then the concentrations of secreted cytokines were measured by cytometry.
